Compare Stocks → The CHIPS Act Motherlode (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:SRPT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeSRPTSarepta Therapeutics$131.38-1.0%$126.50$55.25▼$152.21$12.42B0.951.17 million shs849,008 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceSRPTSarepta Therapeutics0.00%-0.33%+12.72%-2.40%-11.69%Bible Shocker: Have You Seen Elon Musk’s Miracle? (Ad)Breaking News: Elon Musk Invents New Type of A.I. (Shocking) Elon Musk is about to shock the world again with this new type of A.I.… Minting new millionaires in the process.Click here for the full story…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationSRPTSarepta Therapeutics4.5414 of 5 stars3.41.00.04.23.92.51.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceSRPTSarepta Therapeutics2.86Moderate Buy$163.9424.78% UpsideCurrent Analyst RatingsLatest SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/17/2024SRPTSarepta TherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$145.00 ➝ $179.005/14/2024SRPTSarepta TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$180.005/3/2024SRPTSarepta TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$177.00 ➝ $175.005/2/2024SRPTSarepta TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$128.005/2/2024SRPTSarepta TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$166.003/1/2024SRPTSarepta TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$164.00 ➝ $167.002/29/2024SRPTSarepta TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$128.002/29/2024SRPTSarepta TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$151.00 ➝ $157.002/29/2024SRPTSarepta TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$224.002/29/2024SRPTSarepta TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$160.00 ➝ $172.00(Data available from 5/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookSRPTSarepta Therapeutics$1.40B8.85N/AN/A$10.17 per share12.92Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateSRPTSarepta Therapeutics-$535.98M$0.111,194.3616.46N/A1.20%2.20%0.58%8/7/2024 (Estimated)Latest SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2024Q1 24SRPTSarepta Therapeutics-$0.11$0.73+$0.84$0.39$375.52 million$413.50 million 2/28/2024Q4 23SRPTSarepta Therapeutics-$0.03$0.47+$0.50$0.47$387.18 million$396.80 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthSRPTSarepta TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioSRPTSarepta Therapeutics1.184.053.44OwnershipInstitutional OwnershipCompanyInstitutional OwnershipSRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipSRPTSarepta Therapeutics7.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableSRPTSarepta Therapeutics1,31494.52 million87.25 millionOptionableSRPT HeadlinesRecent News About These CompaniesMay 17 at 10:48 AM | markets.businessinsider.comBuy Rating for Sarepta Therapeutics’ Elevidys Supported by Positive Regulatory SignalsMay 17 at 10:07 AM | marketbeat.comThornburg Investment Management Inc. Grows Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 17 at 8:37 AM | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) PT Raised to $179.00 at MizuhoMay 17 at 12:43 AM | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Fiera Capital CorpMay 16 at 3:32 AM | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Lifted to Outperform at OppenheimerMay 15, 2024 | marketbeat.com203,882 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Bought by First Turn Management LLCMay 14, 2024 | marketbeat.comNicholas Investment Partners LP Sells 2,084,756 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 14, 2024 | msn.comRoblox downgraded, Western Digital initiated: Wall Street's top analyst callsMay 14, 2024 | msn.comOppenheimer Upgrades Sarepta Therapeutics (SRPT)May 14, 2024 | msn.comSarepta upgraded at Oppenheimer on potential Elevidys label expansionMay 14, 2024 | marketbeat.comOppenheimer Upgrades Sarepta Therapeutics (NASDAQ:SRPT) to "Outperform"May 11, 2024 | marketbeat.comSwiss National Bank Sells 17,800 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 7, 2024 | insidertrades.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Insider Dallan Murray Sells 3,635 SharesMay 6, 2024 | marketbeat.comInsider Selling: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Insider Sells 3,635 Shares of StockMay 5, 2024 | marketbeat.com10,146 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Acquired by Sapient Capital LLCMay 5, 2024 | finance.yahoo.comEarnings Beat: Sarepta Therapeutics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their ModelsMay 4, 2024 | investorplace.com3 Biotech Stocks With the Potential to Make You an Overnight MillionaireMay 4, 2024 | marketbeat.comVan ECK Associates Corp Has $7.90 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 3, 2024 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Price Target Cut to $175.00May 3, 2024 | bizjournals.comDrug watchdog criticizes Sarepta gene therapy approval, costMay 3, 2024 | finance.yahoo.comGene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global HealthNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsSarepta TherapeuticsNASDAQ:SRPTSarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.